News

The advances scientists have made in identifying dementia symptoms include the hallmarks of Lewy body dementia, the third most prevalent kind behind Alzheimer’s and vascular dementia. Scientists have also discovered biomarkers for diagnosing the disease, including the presence of the protein aggregates known as Lewy bodies that give the condition…

Anavex Life Sciences  has presented new information at a New York conference on Anavex 2-73, which prevented further decline in Alzheimer’s patients’ mental capacity in a clinical trial last year. Dr. Christopher U. Missling, Anavex’s president and chief executive officer, made the presentation at the Jefferies 2017 Global…

The $100 million IDEAS (Imaging Dementia — Evidence for Amyloid Scanning) Study is working closely with researchers and government officials to add three additional studies to the main project, where more than 18,000 people with cognitive deterioration but whose diagnosis is unclear are receiving a brain amyloid PET…

Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained the rights to IBC’s (ImmunoBrain Checkpoint) groundbreaking research into treatment for Alzheimer’s disease. “IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising,” Jacob Tolstrup,…

A new study found personalized music and memory therapy helped decrease antipsychotic and anti-anxiety medication use, as well as improve dementia symptoms, in people living with Alzheimer’s disease (AD) and related dementias (ADRD). Results from the study were published online in the American Journal of Geriatric Psychiatry, under the…

The National Institutes of Health (NIH) has awarded Pain Therapeutics a $1.7 million research grant to study PTI-125 as a potential treatment for Alzheimer’s disease. PTI-125 is an oral, small molecule drug developed by the Austin, Texas-based company in collaboration with other partners. It has been shown to significantly improve…

Insightec’s new platform, Exablate Neuro, is to be a part of the first-ever clinical trial (NCT02986932) evaluating the safety and feasibility of opening the blood-brain barrier (BBB) in Alzheimer’s disease patients at Sunnybrook Health Sciences Centre in Toronto, Canada. Exablate Neuro uses a technique called…

A Keck School of Medicine of USC study shows that cognitive tests can detect early Alzheimer’s disease in  older adults who do not present symptoms yet. The study “Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis” was published in the journal Neuropsychology Review. It is…

Two surveys released today — the start of Alzheimer’s disease month — examine the emotional toll the condition places on caregivers, and their need for greater support. The results are both revealing and alarming. The online survey by the Alzheimer’s Association also delves into the serious lack of preparedness among the public,…

Acadia Pharmaceuticals plans to start a Phase 3 clinical program to explore the effect of Nuplazid (pimavanserin) in Alzheimer’s disease patients with psychosis. The medication was approved by the U.S. Food and Drug Administration in April 2016 to treat similar problems with Parkinson’s patients. “We’re very pleased with…